Kevin Bitterman, Director at Akero Therapeutics, Inc. (AKRO), sold 34,033 shares at $26.28 ($894K) on 2021-06-01, disclosed to the SEC on 2021-06-03.
Open-market sale of $894k AKRO by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $26.28 | 945 | $25K | 2.8% |
| 2 | $26.28 | 16,544 | $435K | 48.6% |
| 3 | $26.28 | 16,544 | $435K | 48.6% |
| Total | $26.28 avg | 34,033 | $894K | 100% |
| Filing → |
| IRON | SELL | 2026-09-03 | $4.4M | — | Filing → |
| IRON | SELL | 2025-12-18 | $69K | — | Filing → |
| IRON | SELL | 2025-12-16 | $33.1M | — | Filing → |